Health Condition 1: L209- Atopic dermatitis, unspecified
Conditions
Interventions
Intervention1: HOMOEOPATHIC MEDICINE: The homoeopathic medicines
as mentioned in literature and
Homoeopathic
Pharamacopoeia of India and
manufactured following Good
Manufacturing Practice (GMP)
compli
Sponsors
CENTRAL COUNCIL FOR RESEARCH IN HOMOEOPATHY
Eligibility
Inclusion criteria
Inclusion criteria: Participants diagnosed with atopic dermatitis who meet diagnostic criteria by Hanifin and Rajka criteria (must have atleast 3 or more major + 3 atleast 3 or more minor criteria) Newly diagnosed case of mild and moderate cases atopic dermatitis Mild AD: SCORAD score between less than 25 Moderate AD: SCORAD score between 26 and 50 Patients or parents or guardians able to give written/ verbal consent Patients already undergoing treatment for AD will be recruited on completely stopping the medicines and after a washout phase of 1 month.
Exclusion criteria
Exclusion criteria: Skin co morbidity that would affect the ability to undertake AD assessments as per investigators judgment. Any malignancy or history of malignancies prior to baseline Any medical or psychiatric condition which in investigators opinion have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma). Patients taking homoeopathic treatment for any chronic disease at time of enrolment will not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of individualized homoeopathic medicines with respect to changes Scoring atopic dermatitis SCORAD at every month for 12 months or in between as per requirement of case.Timepoint: SCORAD at Baseline , at every month for 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the difference between IHMs & placebo in skin barrier dysfunction in atopic dermatitis via Trans epidermal water loss (TEWL) measurement at baseline, 6th month & end of treatment. To assess the difference between IHMs & placebo in Investigator s Global Assessment every month for 12 months or in between as per requirement of case. To assess the changes in Quality of Life by CDLQI/DLQI every month for 12 months. Timepoint: TEWL at baseline , 6 month & end of treatment. IGA every month for 12 months or in between as per requirement of case DLQICDLQI every month for 12 months | — |
Countries
India
Contacts
Public ContactDr Divya Taneja
Central Council for Research in Homoeopathy
Outcome results
None listed